Genitourinary Cancers

At the 2018 Genitourinary Cancers Symposium, lead investigator Alison Jane Birtle, MD, MBBS, MRCP, FRCR, presented the results of the phase 3 POUT clinical trial which showed that adjuvant chemotherapy had impressive gains in the disease-free survival and metastasis-free survival in upper-tract urothelial cancer.

The investigational oral androgen receptor drug ODM-201 has significant antitumor activity with a favorable safety profile in men with metastatic castration-resistant prostate cancer, according to a pooled analysis of 2 early-phase clinical trials.
Results from the large, randomized PIVOT clinical trial that were published in 2012 initially showed that at a median follow-up of 19 years, radical prostatectomy neither improved overall survival nor reduced death related to prostate cancer compared with “watchful waiting” in men with low-risk disease.
Increased levels of physical activity after a diagnosis of prostate cancer are associated with significantly better survival, according to the results of a new, large prospective cohort study.
Hepatocellular carcinoma is the second most common cause of cancer-related death and occurs most often in patients with cirrhosis. Vascular endothelial growth factor (VEGF) plays an important role in tumor growth and angiogenesis, and is overexpressed in patients with hepatocellular carcinoma.
Two pilot programs have shown success in raising awareness of safety concerns aimed at reducing the utilization of inappropriate testosterone replacement therapy.
Two pilot programs aimed at reducing the utilization of in­appropriate testosterone replacement therapy, particularly in the treatment of men with age-related hypogonadism, have shown success in raising awareness of evidence and safety concerns.
Although recent studies have shown the efficacy of using ster­eotactic body radiation therapy (SBRT) as a treatment modality for organ-confined prostate cancer, questions over urinary symptoms and sexual dysfunction have remained.
Sunitinib and pazopanib have long battled for supremacy in treating advanced renal-cell carcinoma (RCC). According to findings presented at the National Comprehensive Cancer Network 20th Annual Conference, the newer drug, pazopanib, may have some benefit in total cost of care; survival outcomes were the same between drugs.
Initial results of the ASSURE study prove surprising and disappointing.
Page 1 of 4
Results 1 - 10 of 40